engleski

Side effects of antipsychotic medication: metabolic syndrome and serotonergic receptors gene polymorphisms

Introduction. Metabolic syndrome (MetS) appears frequently in schizophrenic patients treated with atypical antipsychotics. Its represents a serious health problem due to the increasing risk for the development of diabetes, hypertension and cardiovascular disorders. Although serotonergic receptors are molecular target for atypical antipsychotics, the association between variants of serotonergic receptors type 2A gene (HTR2A) and 2C gene (HTR2C) and MetS in patients treated with antipsychotics is unclear. The purpose of the study was to determine HTR2A and HTR2C polymorphisms and MetS in schizophrenic patients treated with antipsychotics with hypothesis that gene variants of serotonergic receptors are the risk factor for the development of the MetS. Methods. MetS was determined according to the NCEP/ATP III criteria. Waist circumference, triglycerides, high-density lipoprotein cholesterol, plasma glucose levels and blood pressure were assessed in unrelated Caucasians with schizophrenia (DSM-IV criteria) treated with olanzapine, risperidone or clozapine. The allele and genotype frequencies of HTR2A (102C/T ; rs6313), and HTR2C (-759C/T ; rs3813929) polymorphisms were determined in all patients. Results. The genotype frequencies of HTR2A (p = 0, 836 ; hi2 test) and HTR2C (p=0, 133 in female ; p=0, 963 in male patients) were independent on the occurence of MetS. The particular components of the MetS were not associated with the polymorphic variants of HTR2A and HTR2C. Conclusions. Results showed that variations at genes coding for serotonin receptors could not predict the development of MetS after antipsychotic treatment. Further studies are necessary to shed more light on the relationship between phenotypic measurement, metabolic side effects of antipsychotics and serotonin system in schizophrenic patients.

Serotonergic receptors gene polymorphisms; metabolic syndrome

nije evidentirano